Thrombocytopenia up with use of phosphate-buffered tirofiban

Thrombocytopenia up with use of phosphate-buffered tirofiban

(HealthDay)—For patients with acute coronary syndrome, phosphate-buffered tirofiban, but not citrate-buffered tirofiban, is associated with an increased risk of thrombocytopenia, according to a study published in the Aug. 22 issue of JACC: Cardiovascular Interventions.

Marianna Adamo, M.D., from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues randomized 3,232 patients to receive tirofiban or unfractionated heparin (UFH). A total of 879 patients were allocated to phosphate-buffered tirofiban and 874 to the UFH group in the early phase, and 737 and 742 patients were treated with citrate-buffered tirofiban and UFH, respectively, in the late phase.

The researchers found that patients treated with phosphate-buffered tirofiban had an increased relative risk for thrombocytopenia in the early phase (odds ratio, 3.51 [95 percent confidence interval (CI), 1.15 to 10.73] for nadir <90,000/mm³; odds ratio, 2.83 [95 percent CI, 1.11 to 7.22] for nadir <100,000/mm³). The relative risk was not increased for treated with citrate-buffered tirofiban in the late phase (odds ratios, 1.01 [95 percent CI, 0.20 to 5.05] and 0.99 [95 percent CI, 0.26 to 3.45], respectively). The randomization period significantly modified the effect of the treatment on platelet decrease (P for interaction = 0.024).

"Phosphate-buffered tirofiban, currently marketed as a generic drug, is associated with a higher rate of thrombocytopenia with a potentially increased risk for adverse clinical outcomes compared with citrate-buffered tirofiban," the authors write.

More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.

Citation: Thrombocytopenia up with use of phosphate-buffered tirofiban (2016, August 16) retrieved 30 November 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Findings from the BRIGHT trial published


Feedback to editors